| Literature DB >> 28644421 |
Andreas Mauerer1,2, Stefanie Stenglein3, Stefan Schulz-Drost4, Christoph Schörner5, Dominic Taylor6, Sebastian Krinner7, Frank Heidenau8, Werner Adler9, Raimund Forst10.
Abstract
The purpose of our study was to investigate the antibacterial effect of a spacer (Ti6Al4V) coated with 4x Cu-TiO₂ in an animal model simulating an acute periprosthetic infection by Staphylococcus aureus. Ti6Al4 bolts contaminated with Staphylococcus aureus were implanted into the femoral condyle of rabbits (n = 36) divided into 3 groups. After one week in group 1 (control) the bolts were removed without any replacement. In group2 Ti6Al4V bolts with a 4x Cu-TiO₂ coating and in group 3 beads of a gentamicin-PMMA chain were imbedded into the borehole. Microbiological investigation was performed at the primary surgery, at the revision surgery and after scarification of the rabbits 3 weeks after the first surgery. Blood tests were conducted weekly. The initial overall infection rate was 88.9%. In group 2 and 3 a significant decrease of the infection rate was shown in contrast to the control group. The C-reactive protein (CRP) levels declined one week after the first surgery except in the control group where the CRP level even increased. This is the first in vivo study that demonstrated the antibacterial effects of a fourfold Cu-TiO₂ coating. For the future, the coating investigated could be a promising option in the treatment of implant-associated infections.Entities:
Keywords: acute implant-associated infection; animal model; antibacterial Cu-TiO2 coating; copper-ions; total knee arthroplasty
Mesh:
Substances:
Year: 2017 PMID: 28644421 PMCID: PMC6152291 DOI: 10.3390/molecules22071042
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Comparison of the “rate of infection” at the time of revision and post mortem.
Figure 2Mean copper serum levels (μg/dL) of the three groups over the examination period.
Mean value (m) and standard deviation (SD) of each measured parameter of group 1–3 and progression over 4 weeks.
| Units | Group | Preoperative Mean n ± SD | Week 1 Post-Operatively Mean n ± SD | Week 1 Post Revision Mean n ± SD | Week 2 Post Revision Mean n ± SD | |
|---|---|---|---|---|---|---|
| Copper | (μg/dL) | group 1 | 75.98 ±14.86 | 197.21 ± 9.76 | 138.32 ± 73.30 | 126.2 ± 61.14 |
| group 2 | 71.61 ± 17.4 | 209.45 ± 105.2 | 178.06 ± 92.77 | 176.91 ± 92.03 | ||
| group 3 | 73.13 ± 8.3 | 233.51 ± 81.32 | 232.57 ± 102.58 | 153.03 ± 73.76 | ||
| Ceruloplasmin | (mg/dL) | group 1 | 34.68 ± 9.68 | 87.84 ± 56.68 | 65.80 ± 49.20 | 52.55 ± 31.53 |
| group 2 | 26.03 ± 6.68 | 115.71 ± 67.12 | 100.92 ± 48.68 | 99.39 ± 58.08 | ||
| group 3 | 25.98 ± 5.27 | 138.07 ± 67.94 | 153.67 ± 81.37 | 69.53 ± 34.80 | ||
| C-reactive Protein | (μg/mL) | group 1 | 5.2 ± 1.32 | 33.43 ± 28.53 | 11.82 ± 16.44 | 16.14 ± 19.85 |
| group 2 | 4.03 ± 1.07 | 48.49 ± 37.58 | 31.54 ± 21.63 | 31.21 ± 28.87 | ||
| group 3 | 3.89 ± 0.94 | 50.48 ± 27.73 | 36.46 ± 23.25 | 21.20 ± 21.24 | ||
| Leucocytes | (1000/μL) | group 1 | 6.83 ± 1.32 | 8.37 ± 2.47 | 9.23 ± 3.79 | 7.74 ± 2.28 |
| group 2 | 6.31 ± 1.25 | 8.07 ± 1.15 | 10.91 ± 4.11 | 9.24 ± 3.04 | ||
| group 3 | 6.57 ± 1.55 | 8.37 ± 1.97 | 10.37 ± 3.43 | 7.16 ± 2.9 | ||
| Glutamic-Pyruvate Transaminase (GPT) | [U/l] | group 1 | 32.57 ±15.82 | 38.12 ± 82.9 | 35.58 ± 10.82 | 32.25 ± 11.24 |
| group 2 | 38.14 ±11.44 | 72.59 ± 50.20 | 33.83 ± 29.73 | 29.73 ± 12.25 | ||
| group 3 | 40.25 ± 14.59 | 51.5 ± 25.42 | 42.50 ± 24.16 | 34.83 ± 15.58 | ||
| Glutamic-Oxaloacetic Transaminase (GOT) | [U/l] | group 1 | 16.25 ± 4.41 | 31.38 ± 20.54 | 33.75 ± 22.2 | 31.38 ± 16.3 |
| group 2 | 21.76 ± 5.98 | 46.94 ± 30.65 | 27.33 ± 13.4 | 42.09 ± 36.89 | ||
| group 3 | 23.12 ± 4.87 | 42.12 ± 10.05 | 37.38 ± 10.76 | 36.00 ± 12.66 | ||
| Gamma-Glutanyl-Transferase (GGT) | [U/l] | group 1 | 5.88 ± 1.82 | 6.88 ± 2.35 | 7.92 ± 2.23 | 8.38 ± 2.5 |
| group 2 | 6.14 ± 2.15 | 8.76 ± 4.12 | 9.17 ± 3.69 | 8.36 ± 1.22 | ||
| group 3 | 5.75 ± 1.38 | 6.88 ± 1.4 | 9.62 ± 6.27 | 8.17 ± 3.5 | ||
| Creatinine | (mg/dL) | group 1 | 0.75 ± 0.12 | 0.83 ± 0.14 | 0.80 ± 0.18 | 0.91 ± 0.2 |
| group 2 | 1.00 ± 0.29 | 1.08 ± 0.25 | 0.84 ± 0.2 | 0.8 ± 0.15 | ||
| group 3 | 0.81 ± 0.23 | 0.83 ± 0.18 | 1.13 ± 0.66 | 0.81 ± 0.22 |
Figure 3Mean ceruloplasmin concentration (mg/dL) of the three groups over the examination period.
Figure 4Mean C-reactive protein serum levels (μg/mL) of the three groups over the examination period.
Figure 5Mean leukocyte count (1000/μL) of the three groups over the examination period.
Figure 6Mean creatinine concentration (mg/dL) of the three groups over the examination period.
Figure 7Mean Liver Enzyme Level (gamma-glutamyl transferase (GGT), glutamic-pyruvate transaminase (GPT) and glutamic-oxaloacetate transaminase (GOT)) (U/l) of the three groups over the examination period
Figure 8Design of bolt with internal screw thread (a) and lock screw (b). All dimensions shown in mm, L = length, M4 = metric internal screw thread (ISO standards), R = radius.
Figure 9(a) 5mm diameter Titanium alloy (Ti6Al4V) bolts (medrasys GmbH, medical technologies, Pressig, Germany) and 4 mm metric internal screw thread (ISO standards); (b) Example of an original locked bolt and screw.